Výsledky vyhledávání - "Andrea Bondong"

Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Autor: Maria-Luisa Schubert, Stephan Stilgenbauer, Peter Dreger, Andrea Bondong, Carsten Müller-Tidow, Petra Pavel, Anthony D. Ho, Michael Schmitt, Peter Stadtherr, Alexander Kunz, Mandy Wegner, Sascha Dietrich, Susanne Jung, Anita Schmitt

Publikováno v: Biology of Blood and Marrow Transplantation. 26:1575-1580

Although CD19-directed chimeric antigen receptor (CAR) T cells have been successfully used after a preceding allogeneic stem cell transplant (alloHCT) in patients with acute lymphoblastic leukemia, little is known about the feasibility and outcome of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60c8c3ad61ee40408bf81890e39c8c5
https://doi.org/10.1016/j.bbmt.2020.04.025

Zobrazit plný text záznamu

Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation

Autor: Birgit Friedmann-Bette, Joachim Wiskemann, Matthias Limbach, Nikolaus Kleindienst, Andrea Bondong, Peter Dreger, Thomas Luft, Friederike Rosenberger, Martin Bohus, Rea Kuehl

Publikováno v: Supportive Care in Cancer

Purpose Cardiorespiratory fitness (CRF) seems to be prognostic prior to allogeneic stem cell transplantation (allo-HSCT). Influencing factors of CRF in allo-HSCT candidates have not been studied so far. Aim was to identify potentially influencing fac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e921cab01c06e00c9d2a5ff4837d5ab6
http://europepmc.org/articles/PMC7686174

Zobrazit plný text záznamu

Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation

Autor: Caroline Pabst, Nora Liebers, Maria-Luisa Schubert, Laura Simons, Andrea Bondong, Mandy Wegner, Sascha Dietrich, Ute Hegenbart, Stefan Schönland, Aleksandar Radujkovic, Michael Schmitt, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger, Thomas Luft

Publikováno v: Transplantation and Cellular Therapy. 28:S370-S371

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21e4957893ae8e992da72618330dae22
https://doi.org/10.1016/s2666-6367(22)00633-9

Zobrazit plný text záznamu

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Autor: Sascha Dietrich, Carsten Müller-Tidow, Aleksandar Radujkovic, Mandy Wegner, Peter Dreger, Christoph Kimmich, Andrea Bondong, Anthony D. Ho, Thomas Luft, Michael Schmitt, Nora Liebers, Florentina Kosely, Petra Pavel, Peter Stadtherr, Ute Hegenbart, Lorenz Selberg, Anita Schmitt, Maria Luisa Schubert

Publikováno v: Blood Adv

CD19-directed chimeric antigen receptor (CAR) T-cell treatment has evolved as standard of care (SOC) for multiply relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, its potential benefit over allogeneic hematopoietic cell transplantatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a6615951b9aa1297508bc588253b7e
https://pubmed.ncbi.nlm.nih.gov/33351108

Zobrazit plný text záznamu

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

Autor: Thomas Luft, Carsten Müller-Tidow, Sascha Dietrich, T Hien Tran, Andrea Bondong, Julia Meissner, Peter Stadtherr, Michael Schmitt, Ute Hegenbart, Anthony D. Ho, Peter Dreger, Lorenz Selberg, Nora Liebers

Publikováno v: Bone marrow transplantation. 56(1)

Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-transplant (ITT). Included were all consecuti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1bdb0b34137a42862438dcba6bd7138
https://pubmed.ncbi.nlm.nih.gov/32555407

Zobrazit plný text záznamu

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

Publikováno v: Bone Marrow Transplantation. 50:1279-1285

To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Imm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2abfe3bdc47992dee27c2fb66acb54
https://doi.org/10.1038/bmt.2015.150

Zobrazit plný text záznamu

The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison

Publikováno v: Annals of Oncology. 25:200-206

Background In a single-center retrospective donor versus no-donor comparison, we investigated if allogeneic stem cell transplantation (alloSCT) can improve the dismal course of poor-risk chronic lymphocytic leukemia (CLL). Patients and methods All pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ec882e056bd81013a5df7566799aa3
https://doi.org/10.1093/annonc/mdt511

Zobrazit plný text záznamu

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Autor: Andrea Bondong, Thomas Luft, Peter Stadtherr, Michael Schmitt, Peter Dreger, Nora Liebers, Julia Meissner, Lorenz Selberg, Ute Hegenbart, Carsten Mueller-Tidow, Sascha Dietrich

Publikováno v: Blood. 134:3328-3328

Although alloHCT is an accepted salvage treatment in defined settings of poor-risk NHL, its potential benefit in these indications remains controversial because virtually all published studies are uncontrolled and restricted to patients who were actu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::788610fef7231a68c0edeb27864552d3
https://doi.org/10.1182/blood-2019-128352

Zobrazit plný text záznamu

8 Gy TBI/cyclophosphamide (TBI8/CY) as conditioning regimen for allogeneic transplantation in patients with advanced multiple myeloma

Autor: Peter Dreger, Hartmut Goldschmidt, Anthony D. Ho, Kai Neben, Stefan Schoenland, Thomas Schmitt, Klaus Herfarth, Ute Hegenbart, Andrea Bondong

Publikováno v: Journal of Clinical Oncology. 32:e19562-e19562

e19562 Background: Multiple myeloma (MM) is still considered an incurable disease by standard chemotherapy and autologous stem cell transplantation (autoSCT). Outcome for patients (pts) with advers...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a0ad9ba667b1199cbe2dd6031ace1e7
https://doi.org/10.1200/jco.2014.32.15_suppl.e19562

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání